Fierce Pharma Asia—Hansoh's siRNA deals; J&J preps for Legend's CAR-T launch; Brii's COVID antibodies | FiercePharma

China’s Hansoh Pharma has doubled down on siRNA therapeutics with back-to-back licensing deals. Johnson & Johnson is plotting a personalized patient support program for its Legend Biotech-partnered CAR-T therapy cilta-cel. Brii Biosciences’ COVID-19 antibody cocktail could attract more than $1 billion in government contracts next year, SVB Leerink said. And more. 1. Chinese biopharma powerhouse continues charge into siRNA with Silence R&D pact Hansoh Pharma unveiled back-to-back deals focused on siRNA. First, the Chinese pharma giant paid $6.5 million upfront and committed up to $450 million in milestones to team with OliX Pharmaceuticals on cardiovascular, metabolic and other diseases associated…